Single High-dose of Liposomal Amphotericin B in HIV/AIDS-related Disseminated Histoplasmosis: a Randomized Trial.
Alessandro Cumaru PasqualottoDaiane Dalla LanaCassia S M GodoyTerezinha do Menino Jesus Silva LeitãoMonica B BayLisandra Serra DamascenoRenata B A SoaresRoger KistLarissa R SilvaDenusa WiltgenMarineide MeloTaiguara F GuimarãesMarilia R GuimarãesHareton T VechiJacó R L de MesquitaGloria Regina de G MonteiroAntoine AdenisNathan C BahrAndrej SpecDavid R BoulwareDennis IsraelskiTom ChillerDiego R FalciPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
One day induction therapy with 10 mg/kg of L-AmB in AIDS-related histoplasmosis was safe. Although clinical response may be non-inferior to standard L-AmB therapy, a confirmatory phase III clinical trial is needed. A single induction dose would markedly reduce drug-acquisition costs (>4-fold) and markedly shorten and simplify treatment, which are key points in terms of increased access.